152 related articles for article (PubMed ID: 29411964)
1. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.
Cui X; Sun Y; Shen M; Song K; Yin X; Di W; Duan Y
ACS Appl Mater Interfaces; 2018 Mar; 10(9):7821-7831. PubMed ID: 29411964
[TBL] [Abstract][Full Text] [Related]
2. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.
Shi S; Han L; Deng L; Zhang Y; Shen H; Gong T; Zhang Z; Sun X
J Control Release; 2014 Nov; 194():228-37. PubMed ID: 25220161
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer.
Zhai J; Luwor RB; Ahmed N; Escalona R; Tan FH; Fong C; Ratcliffe J; Scoble JA; Drummond CJ; Tran N
ACS Appl Mater Interfaces; 2018 Aug; 10(30):25174-25185. PubMed ID: 29963859
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell.
Liu J; Meng T; Yuan M; Wen L; Cheng B; Liu N; Huang X; Hong Y; Yuan H; Hu F
Int J Nanomedicine; 2016; 11():6713-6725. PubMed ID: 28003747
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death.
Qiu L; Di W; Jiang Q; Scheffler E; Derby S; Yang J; Kouttab N; Wanebo H; Yan B; Wan Y
Int J Oncol; 2005 Nov; 27(5):1441-8. PubMed ID: 16211241
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
7. Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Sánchez-Carranza JN; Díaz JF; Redondo-Horcajo M; Barasoain I; Alvarez L; Lastres P; Romero-Estrada A; Aller P; González-Maya L
Oncol Rep; 2018 Jun; 39(6):3007-3014. PubMed ID: 29693189
[TBL] [Abstract][Full Text] [Related]
8. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.
Jiang X; Xin H; Gu J; Du F; Feng C; Xie Y; Fang X
J Pharm Sci; 2014 May; 103(5):1487-96. PubMed ID: 24619482
[TBL] [Abstract][Full Text] [Related]
10. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
11. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Milane L; Duan Z; Amiji M
Mol Pharm; 2011 Feb; 8(1):185-203. PubMed ID: 20942457
[TBL] [Abstract][Full Text] [Related]
12. A reconstituted thermosensitive hydrogel system based on paclitaxel-loaded amphiphilic copolymer nanoparticles and antitumor efficacy.
Liang Y; Dong C; Zhang J; Deng L; Dong A
Drug Dev Ind Pharm; 2017 Jun; 43(6):972-979. PubMed ID: 28121206
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
14. Polyamino Acid Layer-by-Layer (LbL) Constructed Silica-Supported Mesoporous Titania Nanocarriers for Stimuli-Responsive Delivery of microRNA 708 and Paclitaxel for Combined Chemotherapy.
Gupta B; Ruttala HB; Poudel BK; Pathak S; Regmi S; Gautam M; Poudel K; Sung MH; Ou W; Jin SG; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2018 Jul; 10(29):24392-24405. PubMed ID: 29978708
[TBL] [Abstract][Full Text] [Related]
15. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway.
Qi Z; Yin L; Xu Y; Wang F
Mol Med Rep; 2018 Jun; 17(6):7497-7504. PubMed ID: 29620264
[TBL] [Abstract][Full Text] [Related]
18. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
